P‐Glycoprotein‐Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P‐Glycoprotein‐Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2343 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Hiroki Morishita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, Takasaki, Gunma, Japa…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Drug-Related Side Effects and Adverse Reactions, Long QT Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
The inhibition of human ether‐a‐go‐go‐related gene (hERG) channels is a known cause of QT prolongation triggered by antipsychotic drugs. Our previous studies suggest that P‐glycoprotein (P‐gp)‐mediated drug interactions may lead to increased gastrointestinal absorption of pimozide and its accumulation in cardiomyocytes, thereby enhancing the inhibitory effect of hERG channels. There is a paucity of epidemiological studies examining the risk of QT prolongation by antipsychotic drugs in terms of P‐gp‐mediated interactions with concomitant drugs. Therefore, using the Japanese Adverse Event Reporting Database, we investigated whether the risk of QT prolongation triggered by antipsychotic drugs associated with hERG inhibition is affected by the concomitant use of selective serotonin reuptake inhibitors (SSRIs) associated with P‐gp inhibition. The results showed that the frequency of QT prolongation increased when the antipsychotic drugs quetiapine and sulpiride, which are P‐gp substrates, were combined with SSRIs with P‐gp inhibition. In contrast, no association with QT prolongation was observed in patients on non‐P‐gp‐substrate antipsychotics, irrespective of the P‐gp inhibitory effect of the concomitant SSRI. These results suggest that P‐gp‐mediated interactions are a risk factor for antipsychotic‐induced QT prolongation. There is a need for further investigation into the risks of specific drug combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, Takasaki, Gunma, Japan.
- Department of Pharmacy, Saiseikai Maebashi Hospital, Maebashi, Gunma, Japan.
- Laboratory of Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gunma, Japan.
ORCID-Profile: Hiroki Morishita
Zitieren
APA
Morishita, H., Perera, L. M. B., Sunakawa, H., Kimura, S., Yoshida, H., & Ogihara, T. (2024). P‐Glycoprotein‐Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P‐Glycoprotein‐Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2343
Vancouver
Morishita H, Perera LMB, Sunakawa H, Kimura S, Yoshida H, Ogihara T. P‐Glycoprotein‐Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P‐Glycoprotein‐Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2343
BibTeX
@article{Morishita2024,
author = {Morishita, Hiroki and Perera, Liyanage Manosika Buddhini and Sunakawa, Hiroki and Kimura, Satsuki and Yoshida, Hitoshi and Ogihara, Takuo},
title = {P‐Glycoprotein‐Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P‐Glycoprotein‐Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2343}
}
EUVIMED